Vuxen Group (VUXEN) Q3 25/26 earnings summary

Executive summary

• Achieved 19.1% year-over-year revenue growth in Q3, reaching 80.1 MSEK, with EBITDA up 80% to 6.5 MSEK.

• Focused on expanding customer base and strengthening market position during the key sales period, maintaining fast delivery and high customer satisfaction.

• Core business in sexual health now represents about 90% of revenue, supporting robust margins and recurring income.

• Strategic investments in IT and logistics underpin scalable growth and operational efficiency.

Financial highlights

• Q3 net sales: 80.1 MSEK (67.3 MSEK prior year), up 19.1%.

• Q3 gross margin: 61.7% (58.2%).

• Q3 EBITDA: 6.5 MSEK (3.6 MSEK), EBITDA margin 8.1% (5.3%).

• Nine-month net sales: 189.8 MSEK (169.5 MSEK), up 12%.

• Cash flow from operations for nine months: 20.7 MSEK (5.3 MSEK).

Outlook and guidance

• Management expects continued growth by leveraging the expanded customer base and focusing on long-term customer relationships.

• Confident outlook for the remainder of the fiscal year, aiming to maintain leadership in the sexual health segment.

• New dividend policy adopted, with plans to propose regular dividends from FY 2025/26, subject to financial needs and opportunities.